Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interviews as Topic × Lymphoid × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6 Tumor-Agnostic 4 Thoracic 4 Breast 4 Genitourinary 3 Other hematologic neoplasm 2 Other 2 Gastrointestinal 2 CNS 2 Other neoplasm 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Gynecologic 1

Conditions

Interventions

Cyclophosphamide 83 Rituximab 80 Specimen Handling 56 venetoclax 48 Magnetic Resonance Spectroscopy 46 Biopsy 46 Vincristine 42 Prednisone 42 Doxorubicin 40 fludarabine 38 obinutuzumab 32 Lenalidomide 32 ibrutinib 25 fludarabine phosphate 21 Cytarabine 20 CT-P10 20 Methotrexate 19 Etoposide 19 glofitamab 18 zanubrutinib 17 deltacortene 17 Bendamustine Hydrochloride 17 prednylidene 16 Dexamethasone 16 blinatumomab 14 Granulocyte Colony-Stimulating Factor 13 Gemcitabine 13 pembrolizumab 12 acalabrutinib 12 Prednisolone 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05080166 2026-02-24

UPLYFT For Lymphoma Survivors

Dana-Farber Cancer Institute

Phase NA Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡